We never rest in our quest
to protect the health of people everywhere

Novavax is a global biotechnology company committed to helping address serious infectious diseases globally through the discovery, development and delivery of innovative vaccines to patients around the world.

Our technology

Our vaccine technology leverages our proprietary recombinant protein-based nanoparticle technology and the immunogenicity-enhancing properties of our Matrix-M™ adjuvant.1

Nanoparticles: By organising recombinant proteins in a nanoparticle, it may help the immune system recognise that target protein from different angles—in a similar way that the immune system would see the details of a real pathogen.2 In our vaccines, there’s no actual virus, just the protein; therefore, these vaccines can't cause the infection they aim to prevent.

Matrix-M adjuvant: Our Matrix-M adjuvant comes from saponins, naturally occurring compounds in the bark of the Quillaja saponaria (Soapbark) tree, commonly found in Chile. 

Our areas of research

The world urgently needs new tools to help solve some of our greatest infectious disease challenges. Novavax is applying our technology to address current, emerging and future public health threats. Novavax continually conducts clinical trials, investigations and gathers real-world evidence in order to develop vaccines to address public health threats. Our scientists in our research and development (R&D) programmes are committed to the efficient delivery of new vaccines while maintaining the safety of participants who take part in our trials.

Our areas of research
How to contact Novavax
General enquiries

+44 20 3514 1838
09:00 - 17:00
Monday - Friday

Our location: 
Novavax UK Limited
100 Longwater Avenue
United Kingdom

Media contact
Investor contact

To contact a member of the investor relations team, click on the "Contact us" button below.

Report an adverse effect

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet.

Reporting forms and information can be found at https://yellowcard.mhra.gov.uk.

Adverse events should also be reported to Novavax on +44 203 514 1838 (09:00–17:00 Monday – Friday), or via https://uk.novavaxmedinfo.com/report-adverse-event.

When reporting, please include the vaccine brand and batch/lot number, if available.

By reporting side effects, you can help provide more information on the safety of this vaccine.

Report a product quality complaint

If you have a product quality complaint related to a physical issue with a Novavax product or its packaging, please call +44 203 514 1838 between 09:00–17:00 Monday - Friday.

  1. Krueger S, et al. Structural characterization and modeling of a respiratory syncytial virus fusion glycoprotein nanoparticle vaccine in solution. Mol Pharm. 2021;18(1):359–376.